An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Completed · Phase 2

Conditions studied: Warts

In brief

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks. A second purpose is to evaluate the safety of the drug.

Key facts

Study ID

NCT00116662

Run by

Graceway Pharmaceuticals, LLC

People needed

84

Starts

2005-03-01

Last updated by the study team

2007-02-19

Who can join

Age: 3 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of common wart(s)
• Ages between 3 to 11

You may not qualify if…

• Other types of wart(s), ie. plantar
• Currently participating in another clinical study
• Chronic viral hepatitis B or C

Where it is running

• Arkansas — Fayetteville, Arkansas, United States
• Arkansas — Little Rock, Arkansas, United States
• Georgia — Newnan, Georgia, United States
• Illinois — Buffalo Grove, Illinois, United States
• Indiana — Lafayette, Indiana, United States
• Kansas — Wichita, Kansas, United States
• Massachusetts — Boston, Massachusetts, United States
• Missouri — St Louis, Missouri, United States
• Utah — Layton, Utah, United States
• Vermont — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.